Myelofibrosis Treatment Market by Type (Targeted therapy, Chemotherapy and Others), Distribution Channel (Hospital pharmacies, Retail and specialty pharmacies and Online pharmacies) and Geography (North America, Europe, APAC and RoW)-Forecast up to 2027
Myelofibrosis is an unusual type of blood cancer. The bone marrow becomes scarred, which makes it complicated to make blood cells. It belongs to a group of diseases referred as myeloproliferative disorders or myeloproliferative neoplasms. Stem cells are immature blood-forming cells produced by the bone marrow and can distinguish into red blood cells, white blood cells, or platelets. In myelofibrosis, a DNA alteration (mutation) in a stem cell leads to the cell becoming debilitated or a cancer cell. Factors such as polycythemia vera, thrombocythemia, and exposure to industrial chemicals and high levels of radiation can increase the risk of myelofibrosis. As a result, the increasing incidence of these risk factors among a vital part of the population acts as one of the major factors compelling the market growth. In addition, as primary myelofibrosis is the highly diagnosed disease among people of 50 years and above, the increasing old population and enhancing diagnostic modalities are positively influencing the demand for myelofibrosis treatment methods across the world. On the other hand, the uncertainty in diagnosis of myelofibrosis symptoms limits the market growth. The Myelofibrosis Treatment Market is expected to grow at a rate of 4.2% CAGR by 2027.
Myelofibrosis Treatment Market on the basis of Type
Targeted therapy
Chemotherapy
Others
Myelofibrosis Treatment Market on the basis of Distribution Channel
Hospital pharmacies
Retail and specialty pharmacies
Online pharmacies
Myelofibrosis Treatment Market on the basis of Geography
North America
Europe
Asia Pacific
Rest of the World
In the market for type, the myelofibrosis treatment market is segmented into Targeted therapy, Chemotherapy and Others. Among them the chemotherapy segment is likely to hold the significant share in the market. This is due to the increasing prevalence of cancer among mass. Moreover, the rise in the healthcare expenditure is also leading to the segment growth. Governments are also contributing to develop healthcare infrastructure by raising government funds available to the industry, and this will further impel the segment growth. Moreover, the market chemotherapy products will further driven by expansion of developing nations.
As per the myelofibrosis treatment market by distribution channel, the market is categorized into Hospital pharmacies, Retail and specialty pharmacies and Online pharmacies. The Retail and specialty pharmacies segment is anticipated to have the largest share in the myelofibrosis treatment market. The largest share of the segment is attributed to the easy availability of drugs.
In terms of geography, the myelofibrosis treatment market is divided into North America, Europe, Asia Pacific and Rest of the World. North America region has acquired the maximum share in the agricultural packaging market. This is owing to the presence of major market competitors such as Incyte Corporation, Amneal Pharmaceuticals, Inc, Actuate Therapeutics Inc., AbbVie Inc, Pfizer Inc. and Imago BioSciences and improvement in research of development of cancer drugs in the region fuel the growth of the market. In addition to this, the rise in ??n??rn ?m?ng ????l? for m??nt??n?ng ? healthy lifestyle and consistent growth in th? old population, in the region, this is anticipated to augment growth of the market.
Globally, the healthcare expenditure is rising which is projected to propel the demand for effective treatments for myelofibrosis eventually contributes to the global growth of the myelofibrosis treatment market. In addition to this, the governments across the world are taking initiatives to enhance the access to healthcare and support research and development in the domain of myelofibrosis treatment.
Significant competitors of the myelofibrosis treatment market are Bristol-Myers Squibb Company, Actuate Therapeutics Inc., CTI BioPharma Corp, Incyte Corporation, Amneal Pharmaceuticals, Inc., AbbVie Inc., GlaxoSmithKline plc, Pfizer Inc., Imago BioSciences, and Galecto, Inc.
As a result, the myelofibrosis treatment is expected to witness a significant scope in the future period. This is because; the healthcare research and development organizations are taking significant initiatives to develop various advanced treatments for the rare blood cancer.
The report describes the overall analysis of the myelofibrosis treatment market in respect to the drivers, restraints, opportunities, challenges, trends, size and growth.
This report gives the in-depth details of the segments and sub-segments and their shares in the myelofibrosis treatment market
This report further gives the information of the product innovation, developments and new product promotions in the myelofibrosis treatment
Also point outs the competitive landscape of the market, key vendors, market share, benchmarking, investments and merger acquisitions.
Myelofibrosis Treatment Market on the basis of Type
Targeted therapy
Chemotherapy
Others
Myelofibrosis Treatment Market on the basis of Distribution Channel
Hospital pharmacies
Retail and specialty pharmacies
Online pharmacies
Myelofibrosis Treatment Market on the basis of Geography
North America
Europe
Asia Pacific
Rest of the World
In the market for type, the myelofibrosis treatment market is segmented into Targeted therapy, Chemotherapy and Others. Among them the chemotherapy segment is likely to hold the significant share in the market. This is due to the increasing prevalence of cancer among mass. Moreover, the rise in the healthcare expenditure is also leading to the segment growth. Governments are also contributing to develop healthcare infrastructure by raising government funds available to the industry, and this will further impel the segment growth. Moreover, the market chemotherapy products will further driven by expansion of developing nations.
As per the myelofibrosis treatment market by distribution channel, the market is categorized into Hospital pharmacies, Retail and specialty pharmacies and Online pharmacies. The Retail and specialty pharmacies segment is anticipated to have the largest share in the myelofibrosis treatment market. The largest share of the segment is attributed to the easy availability of drugs.
In terms of geography, the myelofibrosis treatment market is divided into North America, Europe, Asia Pacific and Rest of the World. North America region has acquired the maximum share in the agricultural packaging market. This is owing to the presence of major market competitors such as Incyte Corporation, Amneal Pharmaceuticals, Inc, Actuate Therapeutics Inc., AbbVie Inc, Pfizer Inc. and Imago BioSciences and improvement in research of development of cancer drugs in the region fuel the growth of the market. In addition to this, the rise in ??n??rn ?m?ng ????l? for m??nt??n?ng ? healthy lifestyle and consistent growth in th? old population, in the region, this is anticipated to augment growth of the market.
Globally, the healthcare expenditure is rising which is projected to propel the demand for effective treatments for myelofibrosis eventually contributes to the global growth of the myelofibrosis treatment market. In addition to this, the governments across the world are taking initiatives to enhance the access to healthcare and support research and development in the domain of myelofibrosis treatment.
Significant competitors of the myelofibrosis treatment market are Bristol-Myers Squibb Company, Actuate Therapeutics Inc., CTI BioPharma Corp, Incyte Corporation, Amneal Pharmaceuticals, Inc., AbbVie Inc., GlaxoSmithKline plc, Pfizer Inc., Imago BioSciences, and Galecto, Inc.
As a result, the myelofibrosis treatment is expected to witness a significant scope in the future period. This is because; the healthcare research and development organizations are taking significant initiatives to develop various advanced treatments for the rare blood cancer.
The report describes the overall analysis of the myelofibrosis treatment market in respect to the drivers, restraints, opportunities, challenges, trends, size and growth.
This report gives the in-depth details of the segments and sub-segments and their shares in the myelofibrosis treatment market
This report further gives the information of the product innovation, developments and new product promotions in the myelofibrosis treatment
Also point outs the competitive landscape of the market, key vendors, market share, benchmarking, investments and merger acquisitions.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Targeted therapy
5.3. Chemotherapy
5.4. Others
6. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Hospital pharmacies
6.3. Retail and specialty pharmacies
6.4. Online pharmacies
7. GEOGRAPHY: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. North America
7.3. Europe
7.4. Asia Pacific
7.5. Rest of the World
8. COMPETITIVE LANDSCAPE
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. VENDOR PROFILES
9.1. Bristol-Myers Squibb Company
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. Actuate Therapeutics Inc.
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. CTI BioPharma Corp
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. Incyte Corporation
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. Amneal Pharmaceuticals, Inc.
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. AbbVie Inc.
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. GlaxoSmithKline plc
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. Pfizer Inc.
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. Imago BioSciences
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. Galecto, Inc
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy
10. ANALYST OPINION
11. ANNEXURE
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Targeted therapy
5.3. Chemotherapy
5.4. Others
6. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Hospital pharmacies
6.3. Retail and specialty pharmacies
6.4. Online pharmacies
7. GEOGRAPHY: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. North America
7.3. Europe
7.4. Asia Pacific
7.5. Rest of the World
8. COMPETITIVE LANDSCAPE
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. VENDOR PROFILES
9.1. Bristol-Myers Squibb Company
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. Actuate Therapeutics Inc.
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. CTI BioPharma Corp
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. Incyte Corporation
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. Amneal Pharmaceuticals, Inc.
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. AbbVie Inc.
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. GlaxoSmithKline plc
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. Pfizer Inc.
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. Imago BioSciences
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. Galecto, Inc
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy
10. ANALYST OPINION
11. ANNEXURE
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2026 (USD BILLION)
TABLE 2. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE FOR TARGETED THERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE FOR CHEMOTHERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE FOR RETAIL AND SPECIALTY PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE FOR ONLINE PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. NORTH AMERICA MYELOFIBROSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 10. NORTH AMERICA MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 11. NORTH AMERICA MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 12. U.S MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 13. U.S MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 14. CANADA MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 15. CANADA MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 16. EUROPE MYELOFIBROSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 17. EUROPE MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 18. EUROPE MYELOFIBROSIS TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 19. GERMANY MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 20. GERMANY MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. U.K MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 22. U.K MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 23. FRANCE MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 24. FRANCE MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 25. ITALY MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 26. ITALY MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 27. SPAIN MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 28. SPAIN MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 29. ROE MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 30. ROE MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 31. ASIA PACIFC MYELOFIBROSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 32. ASIA PACIFC MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 33. ASIA PACIFC MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. CHINA MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 35. CHINA MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 36. INDIA MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 37. INDIA MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 38. JAPAN MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 39. JAPAN MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. REST OF APAC MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 41. REST OF APAC MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 42. REST OF WORLD MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 43. REST OF WORLD MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 44. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 45. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 46. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 47. ACTUATE THERAPEUTICS INC.: FINANCIALS
TABLE 48. ACTUATE THERAPEUTICS INC.: PRODUCTS & SERVICES
TABLE 49. ACTUATE THERAPEUTICS INC.: RECENT DEVELOPMENTS
TABLE 50. CTI BIOPHARMA CORP: FINANCIALS
TABLE 51. CTI BIOPHARMA CORP: PRODUCTS & SERVICES
TABLE 52. CTI BIOPHARMA CORP: RECENT DEVELOPMENTS
TABLE 53. INCYTE CORPORATION: FINANCIALS
TABLE 54. INCYTE CORPORATION: PRODUCTS & SERVICES
TABLE 55. INCYTE CORPORATION: RECENT DEVELOPMENTS
TABLE 56. AMNEAL PHARMACEUTICALS, INC.: FINANCIALS
TABLE 57. AMNEAL PHARMACEUTICALS, INC.: PRODUCTS & SERVICES
TABLE 58. AMNEAL PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS
TABLE 59. ABBVIE INC.: FINANCIALS
TABLE 60. ABBVIE INC.: PRODUCTS & SERVICES
TABLE 61. ABBVIE INC.: RECENT DEVELOPMENTS
TABLE 62. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 63. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 64. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 65. PFIZER INC.: FINANCIALS
TABLE 66. PFIZER INC.: PRODUCTS & SERVICES
TABLE 67. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 68. IMAGO BIOSCIENCES: FINANCIALS
TABLE 69. IMAGO BIOSCIENCES: PRODUCTS & SERVICES
TABLE 70. IMAGO BIOSCIENCES: RECENT DEVELOPMENTS
TABLE 71. GALECTO, INC.: FINANCIALS
TABLE 72. GALECTO, INC.: PRODUCTS & SERVICES
TABLE 73. GALECTO, INC.: RECENT DEVELOPMENTS
TABLE 1. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2026 (USD BILLION)
TABLE 2. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE FOR TARGETED THERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE FOR CHEMOTHERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE FOR RETAIL AND SPECIALTY PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL MYELOFIBROSIS TREATMENT MARKET VALUE FOR ONLINE PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. NORTH AMERICA MYELOFIBROSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 10. NORTH AMERICA MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 11. NORTH AMERICA MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 12. U.S MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 13. U.S MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 14. CANADA MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 15. CANADA MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 16. EUROPE MYELOFIBROSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 17. EUROPE MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 18. EUROPE MYELOFIBROSIS TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 19. GERMANY MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 20. GERMANY MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. U.K MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 22. U.K MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 23. FRANCE MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 24. FRANCE MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 25. ITALY MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 26. ITALY MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 27. SPAIN MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 28. SPAIN MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 29. ROE MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 30. ROE MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 31. ASIA PACIFC MYELOFIBROSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 32. ASIA PACIFC MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 33. ASIA PACIFC MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. CHINA MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 35. CHINA MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 36. INDIA MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 37. INDIA MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 38. JAPAN MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 39. JAPAN MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. REST OF APAC MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 41. REST OF APAC MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 42. REST OF WORLD MYELOFIBROSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 43. REST OF WORLD MYELOFIBROSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 44. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 45. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 46. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 47. ACTUATE THERAPEUTICS INC.: FINANCIALS
TABLE 48. ACTUATE THERAPEUTICS INC.: PRODUCTS & SERVICES
TABLE 49. ACTUATE THERAPEUTICS INC.: RECENT DEVELOPMENTS
TABLE 50. CTI BIOPHARMA CORP: FINANCIALS
TABLE 51. CTI BIOPHARMA CORP: PRODUCTS & SERVICES
TABLE 52. CTI BIOPHARMA CORP: RECENT DEVELOPMENTS
TABLE 53. INCYTE CORPORATION: FINANCIALS
TABLE 54. INCYTE CORPORATION: PRODUCTS & SERVICES
TABLE 55. INCYTE CORPORATION: RECENT DEVELOPMENTS
TABLE 56. AMNEAL PHARMACEUTICALS, INC.: FINANCIALS
TABLE 57. AMNEAL PHARMACEUTICALS, INC.: PRODUCTS & SERVICES
TABLE 58. AMNEAL PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS
TABLE 59. ABBVIE INC.: FINANCIALS
TABLE 60. ABBVIE INC.: PRODUCTS & SERVICES
TABLE 61. ABBVIE INC.: RECENT DEVELOPMENTS
TABLE 62. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 63. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 64. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 65. PFIZER INC.: FINANCIALS
TABLE 66. PFIZER INC.: PRODUCTS & SERVICES
TABLE 67. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 68. IMAGO BIOSCIENCES: FINANCIALS
TABLE 69. IMAGO BIOSCIENCES: PRODUCTS & SERVICES
TABLE 70. IMAGO BIOSCIENCES: RECENT DEVELOPMENTS
TABLE 71. GALECTO, INC.: FINANCIALS
TABLE 72. GALECTO, INC.: PRODUCTS & SERVICES
TABLE 73. GALECTO, INC.: RECENT DEVELOPMENTS
